Hydrochloric Acid

Hydrochloric Acid

SCHEMBL60916

CCCCCCCCCCCCC(Cc1ccccc1)C(C)(C)N.Cl

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MMP1 known ✓ P03956 10/20 0.41
HTR2A known ✓ P28223 1/20 0.41
KCNH2 known ✓ Q12809 1/20 0.40
MMP7 known ✓ P09237 6/20 0.39
CSNK1E P49674 1/20 0.54
MMP2 P08253 16/20 0.41
MMP3 P08254 11/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11130193 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL1683449 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL5183324 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL5086708 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL875996 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL11576013 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL82688 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL59932 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL5088573 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A
Hydrochloric Acid SCHEMBL1011374 1.00 CSNK1E (0.54) CSNK1EMMP2MMP3MMP1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144251-A1 ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF POLYAMYNA NANOTECH INC. (CA) 2026-05-28 US claimed
EP-4747927-A2 SYNTHESIS OF NANOSTRUCTURED BATTERY MATERIALS Coreshell Technologies, Inc. (US) 2026-05-27 EP claimed
US-20260007731-A1 INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME BLUEWILLOW BIOLOGICS, INC. (US) 2026-01-08 US claimed
US-12359113-B2 Method for dispersing kinetic hydrate inhibitors CHAMPIONX LLC (US) 2025-07-15 US claimed
CN-116096837-B Nitride etchant composition and method 恩特格里斯公司 2025-05-13 CN claimed
CN-119823109-A An electrochromic material electrochromic composition and electrochromic device 吉林大学 2025-04-15 CN claimed
EP-4507722-A1 NANOEMULSION UNIVERSAL INFLUENZA VACCINE Bluewillow Biologics, Inc. (US) 2025-02-19 EP claimed
WO-2025019829-A2 SYNTHESIS OF NANOSTRUCTURED BATTERY MATERIALS CORESHELL TECHNOLOGIES, INCORPORATED (US) 2025-01-23 WO claimed
US-20240424175-A1 ANTICOAGULANT COMPOUNDS COMPRISING CHELATING AGENTS AND CATIONIC ANTI-COAGULATION ENHANCERS AND METHODS AND DEVICES FOR THEIR USE ELIXIR MEDICAL CORPORATION (US) 2024-12-26 US claimed
US-20240353412-A1 A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) 2024-10-24 US claimed
EP-0647141-A4 NONAQUEOUS COLD STERILANT. SIMMONS PAUL L (US) 1995-08-16 EP claimed
EP-0647141-A1 NONAQUEOUS COLD STERILANT SIMMONS, Paul L. (US) 1995-04-12 EP claimed
US-5389300-A A microbiocidal composition containing a phenolic compound and an iodopropargyl compound BAYER AKTIENGESELLSCHAFT (DE) 1995-02-14 US claimed
WO-1994000157-A1 NONAQUEOUS COLD STERILANT SIMMONS PAUL L (US) 1994-01-06 WO claimed
EP-0299191-B1 MIXTURE OF FUNGICIDALLY ACTIVE AGENTS Henkel Kommanditgesellschaft auf Aktien (DE) 1992-03-04 EP claimed
US-4849531-A Process for the preparation of 2,3-epoxyamides BAYER AKTIENGESELLSCHAFT (DE) 1989-07-18 US claimed
US-4711959-A REACTING 2-ALKYLSULPHONYL-PYRIMIDINE WITH CYANAMIDE OR METAL SALT OF CYANAMIDE BAYER AKTIENGESELLSCHAFT (DE) 1987-12-08 US claimed
EP-0075524-B1 CARBONYLATION PROCESS OF CONJUGATED DIENES IN THE PRESENCE OF A PALLADIUM CATALYST WITH RECYCLING OF SAID CATALYST RHONE-POULENC CHIMIE DE BASE (FR) 1984-09-12 EP claimed
US-4157312-A QUATERNARY AMMONIUM, METAL CHELATE, SWEETENING UOP INC. (US) 1979-06-05 US claimed
US-3984376-A Thermosetting resin compositions prepared from isocyanates and epoxyphenols HITACHI, LTD. (JA) 1976-10-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144251-A1 ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF KLF10, SLC11A2, SLC7A11 MMP1 3820/4885HTR2A 4356/4885KCNH2 99/4885
US-20260007731-A1 INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME CD14, CD47, MYD88 MMP1 4291/4885HTR2A 2832/4885KCNH2 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.